About Carbonic anhydrase-related protein 11
Carbonic anhydrase-related protein 11 (CA11) is a protein
from Homo sapiens identified by UniProt accession
O75493, 328 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Carbonic anhydrase-related protein 11 |
| UniProt accession | O75493 |
| Gene | CA11 |
| Organism | Homo sapiens |
| Length | 328 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.38
- neutrophil percentage of leukocytes · score 0.20
- neutrophil count · score 0.19
- granulocyte percentage of myeloid white cells · score 0.17
- leukocyte count · score 0.14
- Red cell distribution width · score 0.13
- lymphocyte count · score 0.12
- sum of basophil and neutrophil counts · score 0.12
- granulocyte count · score 0.11
- sum of neutrophil and eosinophil counts · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75493-F1 | alphafold | PREDICTED | 87.80 | — |
Amino-acid sequence (328 residues)
MGAAARLSAP RALVLWAALG AAAHIGPAPD PEDWWSYKDN LQGNFVPGPP FWGLVNAAWS LCAVGKRQSP VDVELKRVLY DPFLPPLRLS TGGEKLRGTL YNTGRHVSFL PAPRPVVNVS GGPLLYSHRL SELRLLFGAR DGAGSEHQIN HQGFSAEVQL IHFNQELYGN FSAASRGPNG LAILSLFVNV ASTSNPFLSR LLNRDTITRI SYKNDAYFLQ DLSLELLFPE SFGFITYQGS LSTPPCSETV TWILIDRALN ITSLQMHSLR LLSQNPPSQI FQSLSGNSRP LQPLAHRALR GNRDPRHPER RCRGPNYRLH VDGVPHGR
Explore Carbonic anhydrase-related protein 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets